Chad Oh, MD

Chad Oh, MD, our Chief Medical Officer, has more than 30 years of therapeutic clinical development experience in both industry and academia with a focus on CNS, infectious, respiratory, and autoimmune diseases, cancer and related rare diseases. He effectively facilitated the development of small molecules and biologics (including vaccines and botulinum toxin Type A) for therapeutic indications and led multiple submissions to U.S., European and Asian regulatory authorities to register these products for marketing. Prior to joining AEON, Dr. Oh held senior leadership roles in Clinical Development at Revance, Glenmark Pharmaceuticals and Medimmune/AstraZeneca and the Weinberg Group. Before joining the private sector, he spent 13 years at UCLA School of Medicine where he served as Associate Professor of Pediatrics and Head of the Allergy/Immunology and Rheumatology Clinics at Harbor-UCLA Medical Center. He has authored over 70 peer-reviewed publications and holds several patents. Dr. Oh received his M.D. from the Kyung-Hee University School of Medicine, Seoul, South Korea.